Top

Journal of Medical Case Reports

Published in:

Open Access 01-12-2023 | Acetylcysteine | Case report

Oral administration of bromelain and acetylcysteine in pseudomyxoma peritonei (PMP) caused by low-grade appendiceal mucinous neoplasm (LAMN): a case report

Authors: Dominik Geisel, Ute Langen, Thomas Rüdiger

Published in: Journal of Medical Case Reports | Issue 1/2023

Abstract

Background

Pseudomyxoma Peritonei (PMP) is a severe neoplastic clinical syndrome characterised by secretion of mucin from tumors often originating in the appendix. The standard treatment includes cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC). A new perspective in PMP treatment aims at the mucins themselves as a therapeutic target.

Case presentation

Here we report the first case of PMP with peritoneal dissemination of mucinous implants caused by low-grade appendiceal mucinous neoplasm (LAMN) in a 58-year-old white male exclusively treated by appendectomy and oral administration of bromelain and acetylcysteine in the context of a medical self-experimentation (by co-author T.R.). Observation so far covers a period of 48 months including regular magnetic resonance imaging (MRI) with stable findings.

Conclusions

Oral administration of bromelain and acetylcysteine can be used in the treatment of PMP caused by LAMN without relevant clinical side effects.

Soucisse ML, Lansom J, Alshahrani MS, Morris DL. Mucinous appendiceal neoplasms with or without pseudomyxoma peritonei: a review. ANZ J Surg. 2020;90:1888–94. https://doi.org/10.1111/ans.16185.CrossRefPubMed

Rau B, Kilian M, Köhler C, Mangler M, von Winterfeld M, Rudl M, Raue W. Indikationen und Resultate der Peritonektomie bei nichtkolorektaler Peritonealkarzinose. Viszeral Gastrointest Med Surg. 2013;29:235–44. https://doi.org/10.1159/000354425.CrossRef

Kusamura S, Barretta F, Yonemura Y, Sugarbaker PH, Moran BJ, Levine EA, Goere D, Baratti D, Nizri E, Morris DL, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156:e206363. https://doi.org/10.1001/jamasurg.2020.6363.CrossRefPubMedPubMedCentral

Mercier F, Dagbert F, Pocard M, Goéré D, Quénet F, Wernert R, Dumont F, Brigand C, Passot G, Gléhen OJ. on behalf of the RENAPE Network: recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. BJS Open. 2019;3:195–202. https://doi.org/10.1002/bjs5.97.CrossRefPubMed

Amini A, Masoumi-Moghaddam S, Ehteda A, Morris DL. Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects. Orphanet J Rare Dis. 2014;9:71. https://doi.org/10.1186/1750-1172-9-71.CrossRefPubMedPubMedCentral

Lin Y-L, Li Y. The biological synthesis and the function of mucin 2 in pseudomyxoma peritonei. Cancer Manage Res. 2021;13:7909–17. https://doi.org/10.2147/CMAR.S324982.CrossRef

Pillai K, Akhter J, Chua TC, Morris DL. Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei. Invest New Drugs. 2012;30:2080–6. https://doi.org/10.1007/s10637-012-9797-7.CrossRefPubMed

Pillai K, Akhter J, Chua TC, Morris DL. A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei. Int J Cancer. 2014;134:478–86. https://doi.org/10.1002/ijc.28380.CrossRefPubMed

Sommariva A, Tonello M, Rigotto G, Lazzari N, Pilati P, Calabrò ML. Novel perspectives in pseudomyxoma peritonei treatment. Cancers. 2021;13:5965. https://doi.org/10.3390/cancers13235965.CrossRefPubMedPubMedCentral

10.

Amini A, Masoumi-Moghaddam S, Morris DL. Utility of bromelain and N-acetylcysteine in treatment of peritoneal dissemination of gastrointestinal mucin-producing malignancies. Cham: Springer; 2016. https://doi.org/10.1007/978-3-319-28570-2.CrossRef

11.

Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci. 2001;58:1234–45. https://doi.org/10.1007/PL00000936.CrossRefPubMed

12.

Valle SJ, Akhter J, Mekkawy AH, Lodh SP, Pillai K, Badar S, Glenn D, Power MA, Liauw W, Morris DL. A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: a phase I first in man study. Eur J Surg Oncol. 2021;47:115–22. https://doi.org/10.1016/j.ejso.2019.10.033.CrossRefPubMed

13.

Arjona-Sánchez Á, Martínez-López A, Valenzuela-Molina F, Rufián-Andújar B, Rufián-Peña S, Casado-Adam Á, Sánchez-Hidalgo JM, Rodríguez-Ortiz L, Medina-Fernández FJ, Díaz-López C, et al. A proposal for modification of the PSOGI classification according to the Ki-67 proliferation index in pseudomyxoma peritonei. Ann Surg Oncol. 2022;29:126–36. https://doi.org/10.1245/s10434-021-10372-9.CrossRefPubMed

14.

Ward EP, Okamuro L, Khan S, Hosseini M, Valasek MA, Ronquillo N Jr, Kelly KJ, Veerapong J, Lowy AM, Baumgartner J. Ki67 does not predict recurrence for low-grade appendiceal mucinous neoplasms with peritoneal dissemination after cytoreductive surgery and HIPEC. Hum Pathol. 2021;113:104–10. https://doi.org/10.1016/j.humpath.2021.04.007.CrossRefPubMed

15.

Zih FSW, Wong-Chong N, Hummel C, Petronis J, Panzarella T, Pollett A, McCart JA, Swallow CJ. Mucinous tumor of the appendix with limited peritoneal spread: is there a role for expectant observation? Ann Surg Oncol. 2014;21:225–31. https://doi.org/10.1245/s10434-013-3283-0.CrossRefPubMed

16.

Ke K, Pillai K, Mekkawy AH, Akhter J, Badar S, Valle SJ, Morris DL. The effect of intraperitoneal administration of BromAc® on blood parameters: phase 1 study. Discov Oncol. 2021;12:25. https://doi.org/10.1007/s12672-021-00418-5.CrossRefPubMedPubMedCentral

17.

Vierra M, Dhiman A, Witmer HDD, Ulrich L, Hindi E, Fenton E, Shergill A, Polite B, Eng OS, Turaga KK. Celecoxib and Myrtol—a novel therapy for recurrent appendiceal mucinous neoplasms with extensive peritoneal dissemination. Am J Clin Oncol Cancer Clin Trials. 2022;45:9–13. https://doi.org/10.1097/COC.0000000000000878.CrossRef

18.

Hirano S, Gohda Y, Miyazaki H, Hayama N, Shimizu S, Igari T, Yano H. A case of pseudomyxoma peritonei successfully treated with trifluridine/tipiracil (TAS-102) and bevacizumab after palliative debulking surgery. Chin Clin Oncol. 2021;10:29. https://doi.org/10.21037/cco-21-2.CrossRefPubMed

19.

Lam AR, Bazzi K, Valle SJ, Morris DL. Novel use of bromelain and acetylcysteine (BromAc®) for pleural involvement in pseudomyxoma peritonei. Case Rep Oncol. 2021;14:628–33. https://doi.org/10.1159/000514273.CrossRefPubMedPubMedCentral

Title: Oral administration of bromelain and acetylcysteine in pseudomyxoma peritonei (PMP) caused by low-grade appendiceal mucinous neoplasm (LAMN): a case report
Authors: Dominik Geisel
Ute Langen
Thomas Rüdiger
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Acetylcysteine
Appendectomy
Published in: Journal of Medical Case Reports / Issue 1/2023
Electronic ISSN: 1752-1947
DOI: https://doi.org/10.1186/s13256-023-04024-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Oral administration of bromelain and acetylcysteine in pseudomyxoma peritonei (PMP) caused by low-grade appendiceal mucinous neoplasm (LAMN): a case report

Abstract

Background

Case presentation

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Resolution of stuttering during ketamine treatment: a case report

Effects of the immunoglobulin/histamine complex on panic disorder concurrent with chronic spontaneous urticaria: a case report

The successful treatment of a Gustilo–Anderson type IIIc distal leg injury with a large bone defect in elderly patient with severe osteoporosis: a case report

Crouzon syndrome complicated with binocular strabismus and extraocular muscle fibrosis: a case report

Polycythemia with elevated erythropoietin production in a patient with a urinary stone and unilateral hydronephrosis: a case report

Successful treatment of a multifocal comminuted open fracture of humerus with severe soft tissue defect: a case report